As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

Cannabis-inspired medical products are garnering increasing attention from the scientific community, general public, and health policy makers. A plethora of scientific literature demonstrates intricate engagement of the endocannabinoid system with human immunology, psychology, developmental processes, neuronal plasticity, signal transduction, and metabolic regulation. Despite the therapeutic potential, the adverse psychoactive effects and historical stigma, cannabinoids have limited widespread clinical application. 

In this review, Reddy et al outline of the endocannabinoid system and provide an in-depth discussion of the therapeutic interventions by endocannabinoids in various neurological disorders.

View the latest Editor-in-Chief highlights from EPMA Journal. 

Dr. Golubnitschaja is the head of the world's first Predictive, Preventive and Personalised (3P) Medicine unit at the Department of Radiation Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany.